[Form 4] Beta Bionics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported both stock awards and a small share sale. On February 27, 2026, he received 131,543 shares of common stock as restricted stock units and an option for 70,831 shares that vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,428 shares of common stock at a weighted average price of $12.3616 to cover tax withholding obligations related to restricted stock unit vesting, and held 172,729 common shares directly afterward.

Insights

Equity compensation analyst

Routine equity grants with a small tax-related sale.

Beta Bionics’ CFO Stephen Feider reported standard equity compensation activity. He was granted 131,543 restricted stock units and an option for 70,831 shares, with the option vesting in 36 equal monthly installments beginning on March 1, 2026.

He also sold 1,428 common shares at a weighted average price of $12.3616. A footnote explains the sale was solely to cover tax withholding obligations tied to restricted stock unit vesting, indicating this was not a discretionary reduction in his economic exposure.

After the sale, he directly held 172,729 common shares. These transactions appear consistent with typical executive compensation and tax-management practices rather than signaling a strategic change in ownership.

Insider Trade Summary

Net Seller: 1,428 shares ($17,652)

Net Sell 3 txns

Insider Feider Stephen

Role Chief Financial Officer

Sold 1,428 shs ($18K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,428	$12.3616	$18K
Grant/Award	Employee Stock Option (right to buy)	70,831	$0.00	--
Grant/Award	Common Stock	131,543	$0.00	--

Holdings After Transaction: Common Stock — 172,729 shares (Direct); Employee Stock Option (right to buy) — 70,831 shares (Direct)

Footnotes (1)

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		131,543(1)	A	$0	174,157	D
Common Stock	03/02/2026		S(2)		1,428	D	$12.3616(3)	172,729	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		70,831		(4)	02/26/2036	Common Stock	70,831	$0	70,831	D

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

2. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

	/s/ Stephen Feider	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.